PMH1: RIGOROUS CRITERIA FOR TREATMENT RESPONSE DIFFERENTIATED EFFICACY OF OLANZAPINE VERSUS HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA  by Kinon, BJ et al.
450 Abstracts
OBJECTIVE: A significant portion of the population en-
dures economic, physical, and emotional burdens from
overactive bladder (OAB). OAB, with and without incon-
tinence, causes strong, sudden, and unpredictable urges
to urinate. People with OAB may be at greater risk for
urinary tract infections (UTIs), falls and fractures, and in-
creased medical visits, but to date, the extent to which
consequent treatment costs are associated with OAB is
unknown.
METHODS: The National Overactive BLadder Evalua-
tion (NOBLE) Program included a US survey of 5204 En-
glish-speaking adults over 18 years to estimate the preva-
lence of OAB. All OAB cases and age- and gender-matched
controls were sent a follow-up questionnaire to assess the
occurrence of UTIs, falls, and medical visits in the past
year. A total of 397 (46%) patients and 522 (57%) con-
trols returned the questionnaires. The non-response rate of
patients and controls did not differ with age, gender, edu-
cational status, diabetes, congestive heart failure, or self-
rated health status. UTIs and physician visits were analy-
sed using multivariate regression models, controlling for
age, gender, race, education, marital status, births, self-
reported health status, and presence of diabetes and con-
gestive heart failure.
RESULTS: People with OAB averaged 20% more physi-
cian visits (P  .001), had 57% more UTIs in the last
year (P  .001), and had over twice the odds of being in-
jured in a fall than people without OAB (OR  2.26;
95% CI 1.46, 3.51; P  .001). Sensitivity analyses (re-
moving 5% of the outliers as identified with Cook’s dis-
tance) indicated that the effects were robust. Cost esti-
mates associated with OAB in the year 2000 were
approximately $1.37 billion and $273 million US dollars
for UTIs and falls/broken bones, respectively.
CONCLUSIONS: OAB increases the risk for UTIs and
fall injuries and results in more physician visits. OAB-
related costs were over $1.6 billion US dollars in 2000.
Effective treatment would likely reduce these costs.
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OBJECTIVE: Despite the significant impact of urinary in-
continence (UI) on patient’s Quality of Life (QoL), there is a
lack of internationally validated instruments to assess QoL.
METHODS: CONTILIFE® is a specific UI 28-item QoL
scale, measuring six dimensions: Daily Activities (DA);
Effort Activities (EA); Self Image (SI); Emotional Impact
(EI); Sexuality (SX); Well Being (WB). QoL was assessed
at inclusion and after a four-week treatment period in
505 UI women from Belgium, Denmark, France, Germany,
the Netherlands and the UK (mean age: 51years 
 11; mean
number of urinary leakages over the past 7 days: 16 
 14).
The validity, reliability and sensitivity to change over time
were assessed according to standard guidelines. In addition,
Rasch modeling and Multiple Factor Analysis (MFA) were
used to assess the cross-cultural equivalence and the stability
over time of the CONTILIFE.
RESULTS: According to the number of urinary leakages
(NUL) the clinical validity was very good. All scores were
highly correlated (p  .007) with the NUL. The QoL
scores were responsive to NUL improvement (effect sizes 
0.4), except for the SX and WB dimensions. The con-
struct validity was good (Chronbach alpha  0.7), with
scaling success over 90% in all dimensions except DA
(convergent validity 86%). The severity of the items was
consistent across countries according to Rasch, but MFA
showed a limited equivalence of the underlying construct
across countries. Nevertheless, the stability of the scale’s
structure over the four-week period was excellent.
CONCLUSION: CONTILIFE demonstrated its overall
validity, reliability and sensitivity to change over time in
this international sample. These good properties allow re-
searchers to include this QoL measure as an endpoint in
international clinical trials dealing with female UI.
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OBJECTIVE: To demonstrate that the progressive eleva-
tion of the threshold for definition of treatment response
elucidates the greater likelihood of patients with schizo-
phrenia responding to the novel antipsychotic olanzapine
(OLZ) as compared to haloperidol (HAL).
METHODS: Data was analyzed post-hoc from the acute
phase of a large, prospective, randomized (OLZ versus
HAL, mean modal dose  13.2 versus 11.8 mg/day, re-
spectively), double-blind trial, conducted in 17 countries
with 1996 patients who met the DSM-III-R criteria for
schizophrenia, schizophreniform disorder, or schizoaffec-
tive disorder. The cumulative proportion of patients
achieving a priori defined response criteria at each of
three thresholds was determined. Thresholds for clinical
improvement were 20% or greater, 40% or greater, and
65% or greater reduction in endpoint to baseline Brief
Psychiatric Rating Scale (BPRS) total scores. At each
week, chi-square tests were used to compare the propor-
tion of OLZ-treated patients versus the proportion of
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HAL-treated patients that had responded to therapy at
each of the three thresholds defined. Six-week response-
curves were compared using log-rank tests.
RESULTS: As the threshold for classifying a patient as a
responder increased, the relative divergence between
drug-response curves increased with the OLZ treatment
group consistently attaining higher proportions of re-
sponders than the HAL treatment group. At a minimal
threshold for response (20%), 77% of OLZ versus
70% of HAL-treated patients responded by week 6 (p 
0.002). At a high bar threshold for response (65%),
25.9% of OLZ versus 15.6% of HAL-treated patients re-
sponded by week 6 (p  .001). Furthermore, a separation
of response rates in favor of OLZ could be seen as early
as week 2.
CONCLUSION: Rigorously as compared to minimally de-
fined thresholds for response clearly differentiate the greater
likelihood of patients achieving superior improvement on
the novel antipsychotic OLZ as compared to HAL.
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OBJECTIVE: The objective of this analysis was to ex-
plore the association of improvement in QoL and depres-
sive symptoms with robust acute treatment response of
olanzapine (OLZ) versus haloperidol (HAL).
METHODS: Data was analyzed post-hoc from a double-
blind, randomized (OLZ versus HAL), trial of 1996 pa-
tients with schizophrenia or a related disorder. The treat-
ment response was classified into four groups based on
improvement of the Brief Psychiatric Rating Scale (BPRS)
total scores at 6 weeks: 20%, 20–40%, 40–65% and
65% improvement. Mean percent changes of Quality
of Life Scale (QLS) scores and Montgomery-Asberg De-
pression Rating Scale (MADRS) were determined.
RESULTS: There was a significant positive association
between the more robust level of response (i.e., 65%)
and improvements in depressive symptoms and QLS
across treatment groups. Patients treated with OLZ
started to access moderate improvement (10% im-
provement) in QLS once they attained a 20% or greater
improvement in BPRS while for the HAL-treated pa-
tients, only those who had a 65% or greater response in
BPRS could exceed moderate QLS improvement. The
mean percent change in QLS in the 20–40% BPRS re-
sponse group was 13.4% for OLZ versus 1% for HAL (p 
0.031) and in the 65% or greater BPRS response group
was 41.8% for OLZ versus 32.8% for HAL (p  0.45).
Similar observations were demonstrated in improvement
on the MADRS. For patients with a 40–65% BPRS re-
sponse, the improvement in MADRS was 34.9% for
OLZ versus 6.7% for HAL (p  0.027).
CONCLUSION: A more robust categorical acute treat-
ment response resulted in greater improvement in QoL
and depressive symptoms across treatment groups. For pa-
tients attaining the same level of acute treatment response
though, there may be significantly greater improvements in
QoL and depressive symptoms enjoyed by OLZ-treated
patients compared to those treated with HAL.
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OBJECTIVE: Patients with schizophrenia switched from
conventional antipsychotics, olanzapine, or risperidone,
to ziprasidone show significant improvements in weight,
prolactin levels, and lipid profile. Since such benefits may
affect patient behavior and resource use, Drug Attitude
Inventory (DAI) was administered to assess attitudes/feel-
ings about antipsychotic therapy.
METHODS: Three six-week multi-center, open-label,
parallel-group trials of similar design were undertaken in
stable schizophrenic outpatients switched from conven-
tional antipsychotics (n  108), olanzapine (n  104), or
risperidone (n  58) because of poor tolerability or insuf-
ficient efficacy. Each trial randomized patients to 1 of 3
switch strategies—“slow” taper, “fast” taper, or “abrupt
discontinuation” of prior medication before initiating
ziprasidone (80 mg/day for 2 days; 40–160 mg/day there-
after). The 10-question true/false DAI was administered
at baseline and week six. The primary summary measure
was total score (sum of responses to all questions). Data
were combined from all switch subsets for each study be-
cause there was no significant difference in mean change
from baseline to week six among strategies. Positive total
score indicated likely compliance, whereas negative total
score, likely noncompliance. A categorical linear model
was used to analyze marginal probabilities of favorable
responses over total, attitudinal, and subjective question
sets.
RESULTS: Total DAI scores improved significantly in
patients switched to ziprasidone from conventionals (P 
.003) or risperidone (P  .008). Categorical analysis
identified significant improvements in patients switched
to ziprasidone from conventionals (P  .05 all items, P 
.02 subjective) and a trend toward improved scores in
those switched from olanzapine (P  .06 for both). DAI
improvement from baseline to week six was consistently
driven by positive change in subjective feelings. Ziprasi-
done was safe, well-tolerated, and effective, regardless of
dose or switch strategy.
